OTHER EFFECTS
Along with biopharmaceutical manufacturing growth in Asia comes increased opportunity for vendors such as providers of equipment
and consumables. The BioPlan study shows that more than half of respondents specifically sell to India and China, and 38.7%
of all vendors sell into other Asian markets (2).
Figure 2: Select factors creating future capacity constraints.
|
The growth of India, China, and other emerging countries also contribute to a tightening of the global scientific labor markets.
This year's survey showed that concerns over hiring are increasing as the global economic downturn stabilizes. Expectations
of constraints due to the "inability to hire new, experienced scientific staff" jumped from 19.1% of respondents in 2010 to
27.6% in 2011. The survey, which compiled the factors likely to create biopharmaceutical production constraints by 2015, found
that facility constraints (48.6%) topped the list, followed by the "inability to hire new, experienced technical and production
staff" (31%) and the "physical capacity of downstream purification equipment" (28.1%) (see Figure 2). This tightening in the
market for experienced bioprocessing specialists may be due to expansions in growth of operations and further exacerbated
by specialists increasingly spread out over a growing number of biopharmaceutical companies worldwide.
Eric Langer is president of BioPlan Associates, tel. 301.921.5979, elanger@bioplanassociates.com
, and a periodic contributor to Perspectives on Outsourcing.
REFERENCES
1. BioPlan Associates, 8th Annual Report and Survey of Biopharmaceutical Manufacturing Capacity and Production: A Survey of Biotherapeutic Developers
and Contract Manufacturing Organizations (Rockville, MD), April 2011.
2. BioPlan Associates, Top 1000 Global Biopharmaceutical Facilities Index,
http://www.top1000bio.com/index.asp accessed June 20, 2011.
3. WHO, "China's State Food and Drug Administration Gets WHO Approval for Vaccine Regulatory System" Press Release March
1, 2011.
|
